Homepage Top Section2

This therapy is designed for the treatment of multiple sclerosis (MS), a chronic neurodegenerative autoimmune disease. CAR T-cell therapy involves modifying a patient’s T cells to target and

This partnership covers drug-linker technology and CRDMO services right from discovery to commercialisation. WuXi XDC CEO Dr. Jimmy Li said, “IntoCell’s unique drug-linker technologies and our leading, open-access

This development is part of Galapagos’ strategy to transform into a new biotechnology enterprise with a robust research and development pipeline for treating disease immunology and oncology fields.

Received through the foundation’s Inflammatory Bowel Disease (IBD) Ventures programme, this payment is part of a priorly disclosed grant under research programme agreement with Giiant Pharma to support

Designed based on the Ligand and Enhancer Assisted Delivery (LEAD) platform of SanegeneBio, SGB-3908 is currently in the investigational new drug application (IND)-enabling stage of development. Both Innovent

A HER3 targeting DXd antibody-drug conjugate (ADC), patritumab deruxtecan is intended for usage in patients with locally advanced or metastatic EGFR-mutated NSCLC, who have been treated with two

This vaccine is designed for preventing infections caused by the bacterial pathogen Staphylococcus aureus (S. aureus). S. aureus, a Gram-positive bacterium, affects about 30% of people, causing a

ZORYVE foam offers quick disease clearance and major reduction in itch, with nearly 80% of individuals meeting the primary efficacy endpoint of IGA Success and just more than

This drug is intended for adult patients with RCC after a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine